Holen Sie sich die Stockscreener-App
16.62
4.87%
-0.85
Schlusskurs vom Vortag:
$17.47
Offen:
$16.48
24-Stunden-Volumen:
6.89M
Relative Volume:
2.01
Marktkapitalisierung:
$12.90B
Einnahmen:
$220.00K
Nettoeinkommen (Verlust:
$-1.08B
KGV:
-11.50
EPS:
-1.4448
Netto-Cashflow:
$-326.53M
1W Leistung:
-1.48%
1M Leistung:
-32.38%
6M Leistung:
+2.66%
1J Leistung:
-35.51%
1-Tages-Spanne:
$16.13
$17.40
1-Wochen-Bereich:
$15.55
$17.96
52-Wochen-Spanne:
$13.83
$30.98
Summit Therapeutics Inc Stock (SMMT) Company Profile
Firmenname
Summit Therapeutics Inc
Sektor
Branche
Telefon
305-203-2034
Adresse
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
16.62 | 13.56B | 220.00K | -1.08B | -326.53M | -1.4448 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-08 | Eingeleitet | Stifel | Buy |
| 2026-03-16 | Herabstufung | Jefferies | Buy → Hold |
| 2025-12-17 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-09-17 | Eingeleitet | Barclays | Underweight |
| 2025-09-04 | Eingeleitet | Guggenheim | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Neutral |
| 2025-07-01 | Eingeleitet | UBS | Buy |
| 2025-06-11 | Eingeleitet | Leerink Partners | Underperform |
| 2025-03-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-03-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-03-12 | Eingeleitet | Evercore ISI | Outperform |
| 2025-02-28 | Eingeleitet | Goldman | Buy |
| 2025-01-08 | Eingeleitet | Truist | Buy |
| 2024-12-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-06 | Eingeleitet | Jefferies | Buy |
| 2024-11-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-09-27 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-08-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-07 | Eingeleitet | Citigroup | Buy |
| 2024-03-26 | Eingeleitet | Stifel | Buy |
| 2018-06-28 | Herabstufung | Janney | Buy → Neutral |
| 2018-05-02 | Eingeleitet | Janney | Buy |
| 2018-04-12 | Bestätigt | Needham | Buy |
| 2018-02-13 | Eingeleitet | BTIG Research | Buy |
| 2018-01-04 | Eingeleitet | SunTrust | Buy |
| 2017-12-01 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-11-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-10-05 | Bestätigt | Needham | Buy |
| 2016-09-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-03-30 | Eingeleitet | Needham | Buy |
| 2015-03-30 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Summit Therapeutics Inc Aktie (SMMT) Neueste Nachrichten
Bernstein initiates coverage of Summit Therapeutics (SMMT) with underperform recommendation - MSN
HC Wainwright & Co. downgrades Summit Therapeutics (SMMT) - MSN
SMMT Initiates Coverage On Summit Therapeutics -- Rating Underpe - GuruFocus
Summit Therapeutics (SMMT) Faces Downgrade Amidst Competitive Pr - GuruFocus
Summit Therapeutics (SMMT) Downgraded to Neutral Amid Competitiv - GuruFocus
SMMT Downgraded by HC Wainwright & Co. -- Rating Changes to Neut - GuruFocus
Summit Therapeutics Shares Fall After HC Wainwright Downgrade - marketscreener.com
This Summit Therapeutics Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For FridayCentene (NY - Benzinga
Summit downgraded at H.C. Wainwright after Merck data for sac-TMT - Seeking Alpha
Summit Therapeutics Price Target Announced at $7.70/Share by Bernstein - Moomoo
Why is Summit Therapeutics stock sliding today? By Investing.com - Investing.com Canada
Here's Why You Should Add SMMT Stock to Your Portfolio Now - Yahoo Finance
Cantor Fitzgerald reiterates Overweight on Summit Therapeutics stock By Investing.com - Investing.com Canada
S&P 500 Futures Climb In Premarket Trading; WR Berkley, Summit Therapeutics Lag - Moomoo
H.C. Wainwright downgrades Summit Therapeutics stock rating to neutral By Investing.com - Investing.com Canada
Bernstein Initiates Summit Therapeutics at Underperform - Moomoo
HC Wainwright Downgrades Summit Therapeutics to Neutral From Buy - Moomoo
Summit Therapeutics (SMMT) Faces Scrutiny with Underperform Rati - GuruFocus
Bernstein downgrades Summit Therapeutics stock rating on trial concerns By Investing.com - Investing.com Canada
Summit Therapeutics Inc.Common Stock (NQ: SMMT - The Chronicle-Journal
Cancer Stocks That Are Advancing the Future of Oncology Care - Yahoo! Finance Canada
Summit Therapeutics Inc. (SMMT) Stock Analysis: Healthcare Innovator with Potential 74% Upside - DirectorsTalk Interviews
(SMMT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
A Look At Summit Therapeutics (SMMT) Valuation After HARMONi-3 Trial Risk Highlighted By Analyst Commentary - Yahoo Finance
H.C. Wainwright Reduced its Price Goal on Summit Therapeutics Inc. (SMMT) - Insider Monkey
SMMT Stock Chart | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) - ChartMill
Summit Therapeutics falls after update on Akeso-partnered lung cancer trial - MSN
8 Most Promising Biotech Stocks to Buy Now - Insider Monkey
SMMT Technical Analysis | Trend, Signals & Chart Patterns | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) - ChartMill
Summit Therapeutics (SMMT) Is Down 20.1% After Q1 2026 Net Loss Widens Sharply - simplywall.st
Summit Therapeutics Inc (SMMT) News, Articles, Events & Latest Updates - Stocktwits
Q2 EPS Estimate for Summit Therapeutics Boosted by Analyst - MarketBeat
Q2 Earnings Forecast for SMMT Issued By HC Wainwright - MarketBeat
How (SMMT) Movements Inform Risk Allocation Models - Stock Traders Daily
JPM: AKESO (09926.HK) Lung Cancer Trial Final Analysis Likely to Meet Target; Rating Overweight - AASTOCKS.com
How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III - BioWorld News
SMMT Q1 Loss Narrower Than Expected, Stock Down on Ivonescimab Setback - Yahoo Finance
Summit Therapeutics: More Uncertainty Heading Into The ASCO Plenary (NASDAQ:SMMT) - Seeking Alpha
Investigation into Summit Therapeutics by Johnson Fistel - Intellectia AI
Summit Therapeutics Inc. Shareholders Are Encouraged to - GlobeNewswire
SMMT Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
H.C. Wainwright cuts Summit Therapeutics stock price target on trial risk - Investing.com Canada
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Cuts Target Price to $23 - Moomoo
We're Hopeful That Summit Therapeutics (NASDAQ:SMMT) Will Use Its Cash Wisely - Yahoo Finance
Summit Therapeutics Inc. (SMMT) Stock Analysis: Promising 91% Upside in the Biotech Sector - DirectorsTalk Interviews
Biopharmaceutical News: Summit Therapeutics Stock Plummets After Trial Analysis Misstep - geneonline.com
Analysts Offer Insights on Healthcare Companies: Adagene (ADAG) and Summit Therapeutics (SMMT) - The Globe and Mail
SMMT Plunges As Summit Therapeutics Stock Suffers 27% Selloff - StocksToTrade
Summit Therapeutics Stock Plunges As Selling Pressure Intensifies - timothysykes.com
Roblox, Spotify, And Robinhood Are Among Top 10 Large-Cap Losers Last Week (April 27-May 1): Are The Others In Your Portfolio? - Benzinga
Summit Therapeutics (SMMT) Receives a Rating Update from a Top Analyst - The Globe and Mail
Finanzdaten der Summit Therapeutics Inc-Aktie (SMMT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Summit Therapeutics Inc-Aktie (SMMT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
2.98%
1.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):